-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, On76ei8NEBar8Ou5sssHmoUcpeg3jczbyKo6yKcH68bxV5HNYnQ+UzMGguZDuxBc 3nEDImvAXqD5dIgVaX5fUA== 0000912057-99-010410.txt : 19991224 0000912057-99-010410.hdr.sgml : 19991224 ACCESSION NUMBER: 0000912057-99-010410 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 19991216 FILED AS OF DATE: 19991223 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: ARIAD PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000884731 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 223106987 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 3 SEC ACT: SEC FILE NUMBER: 000-21696 FILM NUMBER: 99779443 BUSINESS ADDRESS: STREET 1: 26 LANDSDOWNE ST CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6174940400 MAIL ADDRESS: STREET 2: 26 LANDSDOWNE CITY: CAMBRIDGE STATE: MA ZIP: 02139 COMPANY DATA: COMPANY CONFORMED NAME: BVF PARTNERS L P/IL CENTRAL INDEX KEY: 0001055947 STANDARD INDUSTRIAL CLASSIFICATION: [] OWNER FILING VALUES: FORM TYPE: 3 BUSINESS ADDRESS: STREET 1: 227 WEST MONROE ST STREET 2: SUITE 4800 CITY: CHICAGO STATE: IL ZIP: 60606 BUSINESS PHONE: 3122637777 3 1 FORM 3
- -------- UNITED STATES SECURITIES AND EXCHANGE COMMISSION ---------------------------- FORM 3 WASHINGTON, D.C. 20549 OMB APPROVAL - -------- ---------------------------- INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES OMB Number: 3235-0104 Expires: September 30, 1998 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Estimated average burden Section 17(a) of the Public Utility Holding Company Act of 1935 or hours per response .... 0.5 (Print or Type Responses) Section 30(f) of the Investment Company Act of 1940 ---------------------------- - ----------------------------------------------------------------------------------------------------------------------------------- 1. Name and Address of Reporting Person* 2. Date of Event Re- 4. Issuer Name AND Ticker or Trading Symbol quiring Statement (Month/Day/Year) BVF Partners L.P. December 16, 1999 Autoimmune Inc. ("AIMM") - ----------------------------------------------------------------------------------------------------------------------------------- (Last) (First) (Middle) 3. IRS or Social Se- 5. Relationship of Reporting Person(s) 6. If Amendment, Date curity Number of to Issuer (Check all applicable) of Original Reporting Person Director X 10% Owner (Month/Day/Year) (Voluntary) ---- ---- Officer (give Other (specify --------------------- title below) below) 7. Individual or ---- ---- Joint/Group Filing (Check Applicable 227 West Monroe Street, Suite 4800 Line) - ------------------------------------------------------------------------------------------------------------- Form filed by One (Street) Reporting Person --- Form filed by More than One X Reporting Person Chicago IL 60606 --- - ----------------------------------------------------------------------------------------------------------------------------------- (City) (State) (Zip) TABLE I -- NON-DERIVATIVE SECURITIES BENEFICIALLY OWNED - ----------------------------------------------------------------------------------------------------------------------------------- 1. Title of Security 2. Amount of Securities 3. Ownership 4. Nature of Indirect Beneficial (Instr. 4) Beneficially Owned Form: Direct Ownership (Instr. 5) (Instr. 4) (D) or Indirect (I) (Instr. 5) - ----------------------------------------------------------------------------------------------------------------------------------- Common Stock 1,694,100 (1) (1) - ----------------------------------------------------------------------------------------------------------------------------------- - ----------------------------------------------------------------------------------------------------------------------------------- - ----------------------------------------------------------------------------------------------------------------------------------- - ----------------------------------------------------------------------------------------------------------------------------------- - ----------------------------------------------------------------------------------------------------------------------------------- - ----------------------------------------------------------------------------------------------------------------------------------- Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. (Page 1 of 3) * If the form is filed by more than one reporting person, SEE Instruction 5(b)(v). SEC 1474 (7-96)
- ----------------------------------------------------------------------------------------------------------------------------------- 1. Name and Address of Reporting Person 2. Date of Event Re- 4. Issuer Name AND Ticker or Trading Symbol quiring Statement (Month/Day/Year) BVF Partners L.P. December 16, 1999 Autoimmune Inc. ("AIMM") - ----------------------------------------------------------------------------------------------------------------------------------- FORM 3 (CONTINUED) TABLE II - DERIVATIVE SECURITIES BENEFICIALLY OWNED (E.G., PUTS, CALLS, WARRANTS, OPTIONS, CONVERTIBLE SECURITIES) - ----------------------------------------------------------------------------------------------------------------------------------- 1. Title of Derivative Security 2. Date Exer- 3. Title and Amount of Securities 4. Conver- 5. Owner- 6. Nature of Indirect (Instr. 4) cisable and Underlying Derivative Security sion or ship Beneficial Expiration (Instr. 4) Exercise Form of Ownership Date Price of Deriv- (Instr. 5) (Month/Day/ Deri- ative Year) vative Security: -------------------------------------------------- Security Direct Amount (D) or Date Expir- or Indirect Exer- ation Title Number (I) cisable Date of (Instr. 5) Shares - ----------------------------------------------------------------------------------------------------------------------------------- - ----------------------------------------------------------------------------------------------------------------------------------- - ----------------------------------------------------------------------------------------------------------------------------------- - ----------------------------------------------------------------------------------------------------------------------------------- Explanation of Responses: (1) The shares reported in this response are beneficially owned by BVF Partners L.P., a Delaware limited partnership ("Partners"), the designated filer of this joint filing on Form 3, and by its general partner, BVF Inc., a Delaware corporation ("BVF Inc."), which is also an investment advisor to Partners. Partners is the general partner of Biotechnology Value Fund, L.P., a Delaware limited partnership ("BVF, L.P.") and investment limited partnership which beneficially owns 1,109,625 of the shares of Common Stock reported in Table I. BVF, L.P., disclaims beneficial ownership of the 584,475 shares of Common Stock reported in Table I beneficially owned by Partners on behalf of certain managed investment accounts. Mark N. Lampert is the sole shareholder and sole director of BVF, Inc., and is an officer of BVF, Inc. This joint filing on Form 3 shall not be deemed an admission that Mark N. Lampert is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise, the beneficial owner of any equity securities covered by this joint filing. BVF Partners L.P. By: BVF Inc., its general partner 12/ /99 ------------------------------------- --------------------- **Intentional misstatements or omissions of facts constitute Federal **Signature of Reporting Person Date Criminal Violations. SEE 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, SEE Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. (Page 2 of 3) SEC 1474 (7-96)
- ----------------------------------------------------------------------------------------------------------------------------------- 1. Name and Address of Reporting Person* 2. Date of Event Re- 4. Issuer Name AND Ticker or Trading Symbol quiring Statement (Month/Day/Year) BVF Partners L.P. December 16, 1999 Autoimmune Inc. ("AIMM") - ----------------------------------------------------------------------------------------------------------------------------------- Listing of the names and addresses of other reporting persons: 1. Biotechnology Value Fund, L.P. Biotechnology Value Fund, L.P. 227 West Monroe Street, Suite 4800 Chicago, Illinois 60606 By: BVF Partners L.P., its general partner By: BVF Inc., its general partner By: /s/ MARK N. LAMPERT 12/22/99 ------------------------------- -------- **Signature of Reporting Person Authorized Signatory 2. BVF Inc. BVF Inc. One Sansome Street, 39th Floor San Francisco, California 94104 /s/ MARK N. LAMPERT 12/22/99 By: --------------------------------------------- -------- **Signature of Reporting Person Date Authorized Signatory 3. Mark N. Lampert One Sansome Street, 39th Floor San Francisco, California 94104 /s/ MARK N. LAMPERT 12/22/99 By: --------------------------------------------- -------- **Signature of Reporting Person Date Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. (Page 3 of 3) * If the form is filed by more than one reporting person, SEE Instruction 5(b)(v). 1474 (7-96)
-----END PRIVACY-ENHANCED MESSAGE-----